Scheltens P

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (16)

Title : Preclinical and randomized clinical evaluation of the p38alpha kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration - Jiang_2022_Nat.Commun_13_5308
Author(s) : Jiang Y , Alam JJ , Gomperts SN , Maruff P , Lemstra AW , Germann UA , Stavrides PH , Darji S , Malampati S , Peddy J , Bleiwas C , Pawlik M , Pensalfini A , Yang DS , Subbanna S , Basavarajappa BS , Smiley JF , Gardner A , Blackburn K , Chu HM , Prins ND , Teunissen CE , Harrison JE , Scheltens P , Nixon RA
Ref : Nat Commun , 13 :5308 , 2022
Abstract : Jiang_2022_Nat.Commun_13_5308
ESTHER : Jiang_2022_Nat.Commun_13_5308
PubMedSearch : Jiang_2022_Nat.Commun_13_5308
PubMedID: 36130946

Title : Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's Disease - Baakman_2021_Br.J.Clin.Pharmacol__
Author(s) : Baakman AC , Gavan C , van Doeselaar L , de Kam M , Broekhuizen K , Bajenaru O , Camps L , Swart EL , Kalisvaart K , Schoonenboom N , Lemstra E , Scheltens P , Cohen A , van Gerven J , Groeneveld GJ
Ref : British Journal of Clinical Pharmacology , : , 2021
Abstract : Baakman_2021_Br.J.Clin.Pharmacol__
ESTHER : Baakman_2021_Br.J.Clin.Pharmacol__
PubMedSearch : Baakman_2021_Br.J.Clin.Pharmacol__
PubMedID: 34964149

Title : Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6 - Brioschi_2021_Alzheimers.Res.Ther_13_172
Author(s) : Brioschi Guevara A , Bieler M , Altomare D , Berthier M , Csajka C , Dautricourt S , Demonet JF , Dodich A , Frisoni GB , Miniussi C , Molinuevo JL , Ribaldi F , Scheltens P , Chetelat G
Ref : Alzheimers Res Ther , 13 :172 , 2021
Abstract : Brioschi_2021_Alzheimers.Res.Ther_13_172
ESTHER : Brioschi_2021_Alzheimers.Res.Ther_13_172
PubMedSearch : Brioschi_2021_Alzheimers.Res.Ther_13_172
PubMedID: 34635149

Title : Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers - Konijnenberg_2017_Alzheimer.Dis.Assoc.Disord_31_146
Author(s) : Konijnenberg E , Fereshtehnejad SM , Kate MT , Eriksdotter M , Scheltens P , Johannsen P , Waldemar G , Visser PJ
Ref : Alzheimer Disease & Associated Disorders , 31 :146 , 2017
Abstract : Konijnenberg_2017_Alzheimer.Dis.Assoc.Disord_31_146
ESTHER : Konijnenberg_2017_Alzheimer.Dis.Assoc.Disord_31_146
PubMedSearch : Konijnenberg_2017_Alzheimer.Dis.Assoc.Disord_31_146
PubMedID: 27158877

Title : EFNS-ENS\/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease - Schmidt_2015_Eur.J.Neurol_22_889
Author(s) : Schmidt R , Hofer E , Bouwman FH , Buerger K , Cordonnier C , Fladby T , Galimberti D , Georges J , Heneka MT , Hort J , Laczo J , Molinuevo JL , O'Brien JT , Religa D , Scheltens P , Schott JM , Sorbi S
Ref : Eur Journal of Neurology , 22 :889 , 2015
Abstract : Schmidt_2015_Eur.J.Neurol_22_889
ESTHER : Schmidt_2015_Eur.J.Neurol_22_889
PubMedSearch : Schmidt_2015_Eur.J.Neurol_22_889
PubMedID: 25808982

Title : The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial - Prins_2014_Alzheimers.Res.Ther_6_47
Author(s) : Prins ND , van der Flier WA , Knol DL , Fox NC , Brashear HR , Nye JS , Barkhof F , Scheltens P
Ref : Alzheimers Res Ther , 6 :47 , 2014
Abstract : Prins_2014_Alzheimers.Res.Ther_6_47
ESTHER : Prins_2014_Alzheimers.Res.Ther_6_47
PubMedSearch : Prins_2014_Alzheimers.Res.Ther_6_47
PubMedID: 25478019

Title : Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews - van de Glind_2013_Dement.Geriatr.Cogn.Disord_36_211
Author(s) : van de Glind EM , van Enst WA , van Munster BC , Olde Rikkert MG , Scheltens P , Scholten RJ , Hooft L
Ref : Dementia & Geriatric Cognitive Disorders , 36 :211 , 2013
Abstract : van de Glind_2013_Dement.Geriatr.Cogn.Disord_36_211
ESTHER : van de Glind_2013_Dement.Geriatr.Cogn.Disord_36_211
PubMedSearch : van de Glind_2013_Dement.Geriatr.Cogn.Disord_36_211
PubMedID: 23941762

Title : Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage - Poil_2013_Front.Aging.Neurosci_5_58
Author(s) : Poil SS , de Haan W , van der Flier WM , Mansvelder HD , Scheltens P , Linkenkaer-Hansen K
Ref : Front Aging Neurosci , 5 :58 , 2013
Abstract : Poil_2013_Front.Aging.Neurosci_5_58
ESTHER : Poil_2013_Front.Aging.Neurosci_5_58
PubMedSearch : Poil_2013_Front.Aging.Neurosci_5_58
PubMedID: 24106478

Title : Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial - Wilkinson_2012_J.Alzheimers.Dis_29_459
Author(s) : Wilkinson D , Fox NC , Barkhof F , Phul R , Lemming O , Scheltens P
Ref : J Alzheimers Dis , 29 :459 , 2012
Abstract : Wilkinson_2012_J.Alzheimers.Dis_29_459
ESTHER : Wilkinson_2012_J.Alzheimers.Dis_29_459
PubMedSearch : Wilkinson_2012_J.Alzheimers.Dis_29_459
PubMedID: 22269160

Title : Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light--a randomized clinical trial - Most_2010_Trials_11_19
Author(s) : Most EI , Scheltens P , Van Someren EJ
Ref : Trials , 11 :19 , 2010
Abstract : Most_2010_Trials_11_19
ESTHER : Most_2010_Trials_11_19
PubMedSearch : Most_2010_Trials_11_19
PubMedID: 20178604

Title : Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study - Ballard_2008_Curr.Med.Res.Opin_24_2561
Author(s) : Ballard C , Sauter M , Scheltens P , He Y , Barkhof F , van Straaten EC , van der Flier WM , Hsu C , Wu S , Lane R
Ref : Curr Med Res Opin , 24 :2561 , 2008
Abstract : Ballard_2008_Curr.Med.Res.Opin_24_2561
ESTHER : Ballard_2008_Curr.Med.Res.Opin_24_2561
PubMedSearch : Ballard_2008_Curr.Med.Res.Opin_24_2561
PubMedID: 18674411

Title : Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study - Goekoop_2006_Brain_129_141
Author(s) : Goekoop R , Scheltens P , Barkhof F , Rombouts SA
Ref : Brain , 129 :141 , 2006
Abstract : Goekoop_2006_Brain_129_141
ESTHER : Goekoop_2006_Brain_129_141
PubMedSearch : Goekoop_2006_Brain_129_141
PubMedID: 16251213

Title : Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients - Visser_2005_Dement.Geriatr.Cogn.Disord_19_126
Author(s) : Visser PJ , Scheltens P , Pelgrim E , Verhey FR
Ref : Dementia & Geriatric Cognitive Disorders , 19 :126 , 2005
Abstract : Visser_2005_Dement.Geriatr.Cogn.Disord_19_126
ESTHER : Visser_2005_Dement.Geriatr.Cogn.Disord_19_126
PubMedSearch : Visser_2005_Dement.Geriatr.Cogn.Disord_19_126
PubMedID: 15627759

Title : Treatment of Alzheimer's disease: current status and new perspectives - Scarpini_2003_Lancet.Neurol_2_539
Author(s) : Scarpini E , Scheltens P , Feldman H
Ref : Lancet Neurol , 2 :539 , 2003
Abstract : Scarpini_2003_Lancet.Neurol_2_539
ESTHER : Scarpini_2003_Lancet.Neurol_2_539
PubMedSearch : Scarpini_2003_Lancet.Neurol_2_539
PubMedID: 12941576

Title : Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease - Rombouts_2002_J.Neurol.Neurosurg.Psychiatry_73_665
Author(s) : Rombouts SA , Barkhof F , Van Meel CS , Scheltens P
Ref : Journal of Neurology Neurosurg Psychiatry , 73 :665 , 2002
Abstract : Rombouts_2002_J.Neurol.Neurosurg.Psychiatry_73_665
ESTHER : Rombouts_2002_J.Neurol.Neurosurg.Psychiatry_73_665
PubMedSearch : Rombouts_2002_J.Neurol.Neurosurg.Psychiatry_73_665
PubMedID: 12438467

Title : Cerebrospinal fluid acetylcholinesterase homospecific activity in patients with probable Alzheimer's disease [letter] -
Author(s) : Konings CH , Scheltens P , Kuiper MA , Mulder C , Calliauw J , Wolters EC
Ref : Biological Psychiatry , 36 :708 , 1994
PubMedID: 7880942